Search Results for "unrelated"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for unrelated. Results 11 to 20 of 22 total matches.
Mirtazapine - A New Antidepressant
The Medical Letter on Drugs and Therapeutics • Dec 20, 1996 (Issue 990)
unrelated to antidepressants previously available in the USA.
COST OF SOME ANTIDEPRESSANTS
Drug Usual ...
Mirtazapine (mir taz a peen; Remeron - Organon) has been approved by the US Food and Drug Administration for treatment of depression. A tetracyclic piperazinoazepine, it is an analog of mianserin, an antidepressant available in Europe, but is structurally unrelated to antidepressants previously available in the USA.
Zonisamide (Zonegran) For Epilepsy
The Medical Letter on Drugs and Therapeutics • Oct 02, 2000 (Issue 1089)
chemically unrelated to other antiepileptic drugs, has been approved by the FDA for adjunctive use in adults ...
Zonisamide (Zonegran - Elan Pharma), a sulfonamide chemically unrelated to other antiepileptic drugs, has been approved by the FDA for adjunctive use in adults with partial seizures. Zonisamide has been available in Japan for more than 10 years.
Vancomycin Dosing and Monitoring
The Medical Letter on Drugs and Therapeutics • Apr 06, 2009 (Issue 1309)
, chills and phlebitis, are unrelated to serum
drug concentrations. Red man syndrome can occur ...
Consensus recommendations for dosing and therapeutic monitoring of intravenous (IV) vancomycin (Vancocin, and others) were recently published. IV vancomycin has been used for decades as an alternative to penicillins for treatment of serious infections due to gram-positive cocci. In recent years, the widest use of the drug has been for treatment of serious methicillin-resistant Staphylococcus aureus (MRSA) infections.
Fostamatinib (Tavalisse) for ITP
The Medical Letter on Drugs and Therapeutics • Feb 25, 2019 (Issue 1566)
count ≥50,000/mcL (unrelated to rescue
therapy), within 12 weeks after reaching the target platelet ...
The FDA has approved fostamatinib disodium
hexahydrate (Tavalisse – Rigel), the first spleen
tyrosine kinase (SYK) inhibitor, for oral treatment of
thrombocytopenia in adults with chronic immune
thrombocytopenia (ITP) who have had an insufficient
response to a previous treatment.
Two New Drugs for Epilepsy
The Medical Letter on Drugs and Therapeutics • Apr 17, 2000 (Issue 1076)
unrelated to other
antiepileptic drugs, are the sixth and seventh drugs approved by the US Food and Drug ...
Oxcarbazepine, which is chemically similar to carbamazepine, and levetiracetam, a pyrrolidine acetamide chemically unrelated to other antiepileptic drugs, are the sixth and seventh drugs approved by the US Food and Drug Administration in the last five years for oral use in partial seizures.
Rufinamide (Banzel) for Epilepsy
The Medical Letter on Drugs and Therapeutics • Mar 09, 2009 (Issue 1307)
– Eisai), a triazole derivative
structurally unrelated to other marketed antiepileptic
drugs (AEDs ...
Rufinamide (Banzel - Eisai), a triazole derivative structurally unrelated to other marketed antiepileptic drugs (AEDs), has been approved by the FDA for treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients ≥4 years old.
Febuxostat (Uloric) for Chronic Treatment of Gout
The Medical Letter on Drugs and Therapeutics • May 18, 2009 (Issue 1312)
years.
Febuxostat is structurally unrelated to allopurinol, the
only other commercially available ...
Febuxostat (Uloric - Takeda), a xanthine oxidase inhibitor, has been approved by the FDA for chronic management of hyperuricemia in patients with gout. It is the first drug marketed for treatment of gout in 40 years. Febuxostat is structurally unrelated to allopurinol, the only other commercially available inhibitor of xanthine oxidase. Xanthine oxidase inhibitors decrease serum urate concentrations by decreasing urate synthesis.
Drugs for Cough
The Medical Letter on Drugs and Therapeutics • Dec 17, 2018 (Issue 1562)
of cough unrelated to
asthma have produced conflicting results.14,15
Adverse Effects – Local adverse ...
Acute cough (<3 weeks in duration) generally does
not require pharmacologic treatment, especially in
children. Suppression of productive cough may be
harmful. Management of patients with cough should
include elimination of any precipitating factor (e.g.,
cigarette smoking) and treatment of any underlying
cause such as upper airway cough syndrome,
gastroesophageal reflux disease, asthma, or other
pulmonary disease.
Comparison Table: Some Lipid-Lowering Drugs (online only)
The Medical Letter on Drugs and Therapeutics • Sep 19, 2022 (Issue 1659)
symptoms reported by statin users
are unrelated to the drugs
Rhabdomyolysis and myoglobinemia leading ...
View the Comparison Table: Some Lipid-Lowering Drugs
Drugs of Choice for Cancer Chemotherapy
The Medical Letter on Drugs and Therapeutics • Mar 31, 1995 (Issue 945)
years from diagnosis, and use of one-antigen-mismatched or matched unrelated
donor marrow. Interferon ...